All In Biotech

Drug Trial Radar · NCT04370379

Trial to Evaluate the Safety and Tolerability of Repeated Intravitreal Injection of IBI302 in Neovascular AMD Patients

A Dose Escalation Phase I Clinical Study to Evaluate the Tolerability and Safety of IBI302 in Patients With Neovascular Age-related Macular Degeneration (nAMD)

Last checked: Nov 19, 2026Latest source record: Nov 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

18

Actual

Start

May 28, 2020

Primary completion

Apr 30, 2021

Study completion May 8, 2021

Sponsor

Sponsor type
Industry
First posted
Apr 30, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed for multi-center, open-label, randomized, dose escalation phase I trial to evaluate the safety and tolerability of a multiple dose intravitreal injection of IBI302 in neovascular AMD patients.

Conditions

  • Neovascular Age-related Macular Degeneration

Interventions

  • IBI302 (the first dose level)Drug

    q4week (3 injections) followed by PRN dosing

  • IBI302 (the second dose level)Drug

    q4week (3 injections) followed by PRN dosing

  • AfliberceptDrug

    2mg, q4week (3 injections) followed by q8week

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ocular safety, assessed by BCVA, slitlamp examination, ophthalmoscopy, IOP, fundus photographyTime frame: Baseline to Day140
  2. Incidence of adverse eventsTime frame: Baseline to Day140

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai General Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.